栝蒌薤白半夏汤加减治疗痰浊内阻型稳定型心绞痛的临床疗效及对肠道菌群的影响  

Clinical Efficacy of Modified Gualou Xiebai Banxia Decoction in the Treatment of Stable Angina Pectoris with Internal Resistance of Phlegm and Turbidity and Its Effect on Gut Microbiota

作　　者：王恒生 凡永杰 刘原 刘若雅 韦夏薇 刘鹰 唐耀平[1,2,3] Wang Hengsheng;Fan Yongjie;Liu Yuan;Liu Ruoya;Wei Xiawei;Liu Ying;Tang Yaoping(Ruikang Clinical Medical College of Guangxi University of Chinese Medicine,Nanning 530200,China;Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530011,China;Guangxi Key Laboratory of Translational Medicine of Integrated Traditional Chinese and Western Medicine for High Infectious Diseases,Nanning 530032,China)

机构地区：[1]广西中医药大学瑞康临床医学院,南宁530200 [2]广西中医药大学附属瑞康医院,南宁530011 [3]广西高发传染病中西医结合转化医学重点实验室,南宁530032

出　　处：《世界科学技术-中医药现代化》2023年第11期3626-3636,共11页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：国家自然科学基金委员会地区科学基金项目(82160856):基于肠道菌群探索栝楼薤白白酒汤从脾论治冠心病的机制研究,负责人:唐耀平

摘　　要：目的探讨栝蒌薤白半夏汤加减治疗痰浊内阻型稳定型心绞痛(Stable angina pectoris,SAP)的临床疗效及对肠道菌群影响。方法选取我院72例痰浊内阻型SAP患者临床资料进行前瞻性研究,按照入院先后顺序排序,采用随机数字表法分为对照组及观察者,两组各36例。对照组予以西医规范化治疗,观察组在对照组基础上给予栝蒌薤白半夏汤加减进行治疗。通过对比两组患者的临床疗效及肠道菌群构成进行分析。结果治疗后,观察组的临床疗效优于对照组(P<0.05);两组心电图疗效无明显差异(P>0.05);基于16S rDNA技术,在门、属水平上,两组治疗前的拟杆菌门(Bacteroidota)、拟杆菌属(Bacteroides)、粪杆菌属(Faecalibacterium)等丰度无差异(P>0.05),治疗后观察组较对照组的拟杆菌门(Bacteroidota)丰度上升更明显(P<0.05)。结论栝蒌薤白半夏汤加减通过调节肠道菌群,能有效提高SAP痰浊内阻型患者的临床疗效,为进一步研发栝蒌薤白半夏汤提供了新的启示。Objective To investigate the clinical curative effect of Modified Gualou Xiebai Banxia Decoction in the treatment of stable angina pectoris(SAP)with internal resistance of phlegm and turbidity and its effect on gut microbiota.Methods The clinical data of 72 cases of SAP patients with phlegm turbidity and internal resistance type in our hospital were selected for prospective study,sorted according to the order of admission,and divided into control group and observer by random number table method,with 36 cases in each group.The control group was given standardized western medicine treatment,and the observation group was given the addition of Modified Gualou Xiebai Banxia Decoction on the basis of the control group.The clinical efficacy and gut microbiota composition of the two groups of patients were compared.Results After treatment,the clinical efficacy of the observation group was better than that of the control group(P<0.05);there was no significant difference in the ECG efficacy between the two groups(P>0.05).Based on 16S rDNA technology,at the phylum and genus levels,there was no difference in the abundance of Bacteroidota,Bacteroides and Faecalibacterium(P>0.05).After treatment,the abundance of Bacteroidota in the observation group increased more significantly than that in the control group(P<0.05).Conclusion Modified Gualou Xiebai Banxia Decoction can effectively improve the clinical efficacy of SAP patients with phlegm-turbid internal resistance by regulating gut microbiota,which provides new inspiration for the further development of Gualou Xiebai Banxia Decoction.

关 键 词：栝蒌薤白半夏汤加减 稳定型心绞痛 痰浊内阻型 临床疗效 肠道菌群 

分 类 号：R285.6[医药卫生—中药学]